Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

August 11, 2017: By Jon Swedien

Allegro logoAllegro Ophthalmics on Aug. 9 reported positive results from its Phase IIb Stage 2 clinical trial for Luminate.

Luminate—a first-in-class integrin peptide therapy that treats neovascular retinal diseases—met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME) in the DEL MAR Stage 2 study, according to the San Juan Capistrano, California, company.

The primary endpoint was non-inferiority to bevacizumab in mean change in best-corrected visual acuity (BCVA) at 20 weeks when Luminate was used with a single bevacizumab pretreatment (sequential therapy) or in combination with bevacizumab.

The Luminate results were achieved after one treatment of 1.25 mg bevacizumab (week zero) followed by three 1 mg Luminate injections (weeks one, four, and eight) and 12 weeks off treatment, compared with five injections given every four weeks with bevacizumab.

The data showed the mean gain in BCVA was 7.1 letters for patients in the Luminate with bevacizumab pretreatment (sequential) group compared with 6.7 letters for patients in the bevacizumab control group.

The double-masked, placebo-controlled, randomized, multicenter, five-month Phase IIb, Stage 2 trial, conducted at 14 US sites, included five arms:

— Luminate 0.5 mg or 1.0 mg as a sequential therapy after a single treatment of 1.25 mg bevacizumab (week zero) followed by three Luminate injections (weeks one, four, and eight), and 12 weeks off treatment;

— Luminate 0.5 mg or 1.0 mg given in direct combination with bevacizumab 1.25 mg at weeks one, four, and eight, and 12 weeks off treatment;

— A 1.25 mg bevacizumab control arm of five monthly injections.

The trial also found that Luminate was well-tolerated with no drug toxicity or intraocular inflammation. These safety results are consistent with previously conducted Luminate studies on human subjects where there were no reports of significant inflammation and no evidence of retinal tears or detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022